IL236523B - Methods for producing antibody molecules with intra-target cross-sexual reactivity - Google Patents

Methods for producing antibody molecules with intra-target cross-sexual reactivity

Info

Publication number
IL236523B
IL236523B IL236523A IL23652314A IL236523B IL 236523 B IL236523 B IL 236523B IL 236523 A IL236523 A IL 236523A IL 23652314 A IL23652314 A IL 23652314A IL 236523 B IL236523 B IL 236523B
Authority
IL
Israel
Prior art keywords
intra
reactivity
inter
species
antibody molecules
Prior art date
Application number
IL236523A
Other languages
English (en)
Hebrew (he)
Other versions
IL236523A0 (en
Inventor
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Der Woning Sebastian Paul Van
Original Assignee
Haard Johannes Joseph Wilhelmus De
Christophe Frederic Jerome Blanchetot
Der Woning Sebastian Paul Van
Argenx Bvba
Argenx Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haard Johannes Joseph Wilhelmus De, Christophe Frederic Jerome Blanchetot, Der Woning Sebastian Paul Van, Argenx Bvba, Argenx Se filed Critical Haard Johannes Joseph Wilhelmus De
Publication of IL236523A0 publication Critical patent/IL236523A0/en
Publication of IL236523B publication Critical patent/IL236523B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL236523A 2012-08-31 2014-12-31 Methods for producing antibody molecules with intra-target cross-sexual reactivity IL236523B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (2)

Publication Number Publication Date
IL236523A0 IL236523A0 (en) 2015-02-26
IL236523B true IL236523B (en) 2018-12-31

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
IL236523A IL236523B (en) 2012-08-31 2014-12-31 Methods for producing antibody molecules with intra-target cross-sexual reactivity

Country Status (10)

Country Link
US (1) US20150203840A1 (cg-RX-API-DMAC10.html)
EP (2) EP2977386A1 (cg-RX-API-DMAC10.html)
JP (1) JP6391574B2 (cg-RX-API-DMAC10.html)
CN (1) CN104583238A (cg-RX-API-DMAC10.html)
AU (2) AU2013310924B2 (cg-RX-API-DMAC10.html)
CA (1) CA2878712A1 (cg-RX-API-DMAC10.html)
DK (1) DK2890711T3 (cg-RX-API-DMAC10.html)
IL (1) IL236523B (cg-RX-API-DMAC10.html)
IN (1) IN2015DN00140A (cg-RX-API-DMAC10.html)
WO (1) WO2014033252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
US20260176369A1 (en) 2022-11-08 2026-06-25 Stichting Amsterdam UMC Activation Inducible Antigen Receptors for Adoptive Immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1798768B (zh) * 2003-03-24 2013-05-08 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其应用
DE602004028347D1 (de) * 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2781682A1 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
MX385858B (es) * 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Also Published As

Publication number Publication date
WO2014033252A1 (en) 2014-03-06
DK2890711T3 (en) 2017-02-27
CN104583238A (zh) 2015-04-29
EP2977386A1 (en) 2016-01-27
EP2890711B1 (en) 2017-01-04
AU2013310924A8 (en) 2015-04-30
AU2017204188A1 (en) 2017-07-13
AU2013310924B2 (en) 2017-08-03
US20150203840A1 (en) 2015-07-23
IL236523A0 (en) 2015-02-26
CA2878712A1 (en) 2014-03-06
IN2015DN00140A (cg-RX-API-DMAC10.html) 2015-06-12
EP2890711A1 (en) 2015-07-08
JP6391574B2 (ja) 2018-09-26
AU2013310924A1 (en) 2015-01-29
JP2015530087A (ja) 2015-10-15

Similar Documents

Publication Publication Date Title
IL236523A0 (en) Methods for producing antibody molecules with intra-target cross-sexual reactivity
IL267225B (en) Bispecific igg4 antibodies are asymmetrically sequenced
IL242649A (en) Purification process of monoclonal antibody
SI2794658T1 (sl) Bispecifična molekula protitelesa
PL2718404T3 (pl) Sposób wytwarzania ciekłych węglowodorów
IL232558B (en) A method for antibody purification
IL230553B (en) Bispecific antigen binding molecules
LT3378535T (lt) Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
AP3898A (en) Method for producing substituted 5-fluoro-1H-pyrazolopyridines
EP3004163A4 (en) Method for purifying antibody
HUE055717T2 (hu) Eljárás antitestek elõállítására
PL3263542T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
PL2766331T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
FI20125708L (fi) Prosessi hiilivetyjen valmistamiseksi
EP2751058A4 (en) PROCESS FOR PRODUCING 2,3,3,3-TETRAFLUOROPROPENE
ZA201307419B (en) Method for producing hydrocarbons
IL239689A0 (en) A method for producing antibodies
EP3020540A4 (en) Method for producing reinforcing structure
PL2773605T3 (pl) Sposób wytwarzania 2,3,3,3-tetrafluoropropenu
PT2766330T (pt) Processo para a produção de 2,3,3,3-tetrafluoropropeno
EP2751057A4 (en) PROCESS FOR THE PREPARATION OF 2,3,3,3-TETRAFLUOROPROPES
AP2013007204A0 (en) Method for producing hydrogenarion catalyst
IL230159A0 (en) Method for the production of 2-amino-5-cyano-n,3-dimethylbenzamide
SG11201402984SA (en) Method for producing pudding
TH1301005419B (th) วิธีการผลิตวัสดุไฮโดรคาร์บอน

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed